ClinicalTrials.gg
CompletedNCT03182504Updated Apr 23, 2018

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

A Phase 1 interventional study of nacubactam and meropenem in Gram-negative Bacterial Infections, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-23.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2017, 9 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Gram-Negative Bacterial Infections with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Gram-Negative Bacterial Infections · United States.

Enrollment
13th of 16
21 · median 48
Started
2017
with 3 others
Phase 1
2 of 23
none open now
Registered
9th of 23
by date
Lead sponsor
1 of 23
Hoffmann-La Roche

Among the 23 studies in Gram-Negative Bacterial Infections with a site in United States, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 1, and was the 9th registered.

Gram-Negative Bacterial Infections

58 studies on the registry are indexed under Gram-Negative Bacterial Infections; 10 are open to participants now.

Browse Gram-Negative Bacterial Infections studies →

Open to participants now

3 of the 23 studies in Gram-Negative Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Gram-Negative Bacterial Infections studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Gram-Negative Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.

03

Conditions studied

  • Gram-negative Bacterial Infections
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 60 years of age, inclusive
  • Healthy, as judged by the Investigator and defined by the absence of evidence of any active or chronic disease identified from a detailed medical and surgical history, physical examination including vital signs and 12-lead (ECG), and laboratory safety test results
  • (BMI) within the range 18-30 kilogram per square meter (kg/m\^2),inclusive
  • Non-smoker, or former smoker who has abstained from smoking for at least 6 months
  • Negative pregnancy test and agreement to comply with measures to prevent pregnancy in women
  • Refrain from sperm donation and agreement to comply with measures to prevent pregnancy in partner of for men

Exclusion criteria

Exclusion Criteria:

  • History of asthma or lung disease
  • Any condition which contraindicates a BAL procedure
  • History of clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, dermatological, immunological or allergic disease, metabolic disorder, cancer or cirrhosis
  • Clinically significant change in health status, as judged by the Investigator, or any major illness within the four weeks before screening, or clinically significant acute infection or febrile illness within the 14 days before screening
  • History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders
  • Participation in any other clinical study involving an medicinal product or device within 3 months before screening
  • Known history of clinically significant or urticaria, or severe allergic reaction to any drug, in particular antibiotics
  • Donation or loss of over 500 milliliter (mL) of blood within the three months before screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Nacubactam Plus Meropenem

    Participants will receive a single dose of nacubactam co-administered with meropenem.

    Drug: nacubactam · Drug: meropenem

Interventions

  • Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.

    Also known as: RO7079901

  • Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.

    Also known as: Merrem

06

What researchers measure

Primary outcomes

  1. Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam Ratio

    The ELF to plasma ratio will be calculated from the concentration of nacubactam in ELF and plasma as a measure of the intrapulmonary penetration of nacubactam in healthy participants.

    Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration

Secondary outcomes

  1. ELF Concentration of Meropenem to Plasma Concentration of Meropenem Ratio

    The ELF to plasma ratio will be calculated from the concentration of meropenem in ELF and plasma as a measure of the intrapulmonary penetration of meropenem in healthy participants..

    Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration

  2. Area Under the Plasma Concentration-Time Curve from time 0 to 8 hours (AUC0-8) of Nacubactam in ELF

    Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration

  3. Maximum Concentration (Cmax) of Nacubactam in ELF

    Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration

  4. Area Under the Plasma Concentration-Time Curve from Time 0 to 8 Hours (AUC0-8) of Nacubactam in Blood Plasma

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  5. Maximum Concentration (Cmax) of Nacubactam in Blood Plasma

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  6. Time to Reach the Maximum Plasma Concentration (Tmax) of Nacubactam

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  7. Clearance (CL) of Nacubactam

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  8. Volume of Distribution of the Central Compartment (Vc) of Nacubactam

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  9. Volume of Distribution at Steady-State (Vss) of Nacubactam

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  10. Area Under the Plasma Concentration-Time Curve from Time 0 to 8 Hours (AUC0-8) of Meropenem in ELF

    Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration

  11. Maximum Concentration (Cmax) of Meropenem in ELF

    Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration

  12. Area Under the Plasma Concentration-Time Curve from Time 0 to 8 hours (AUC0-8) of Meropenem in Blood Plasma

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  13. Maximum Concentration (Cmax) of Meropenem in Blood Plasma

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  14. Time to Reach the Maximum Plasma Concentration (Tmax) of Meropenem

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  15. Clearance (CL) of Meropenem

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  16. Volume of Distribution of the Central Compartment (Vc) of Meropenem

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  17. Volume of Distribution at Steady-State (Vss) of Meropenem

    Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration

  18. Number of Participants with Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: From baseline up to 14 days after study drug administration

07

Study locations

1 site
  • Pulmonary Associates Clinical Trials (PACT)
    Phoenix, Arizona 85006, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Aug 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2017
First posted
Jun 9, 2017
StartActual
Jun 15, 2017
Primary completionActual
Aug 10, 2017
CompletionActual
Aug 10, 2017
Last update
Apr 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03182504
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Jun 15, 2017
Primary completion
Aug 10, 2017
Completion
Aug 10, 2017
Last update
Apr 23, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nacubactam

Start the discussion